Somewhat Positive News Coverage Somewhat Unlikely to Affect Biopharmx Corp (BPMX) Stock Price

Media headlines about Biopharmx Corp (NYSE:BPMX) have trended somewhat positive on Wednesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biopharmx Corp earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.1194679220729 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Biopharmx Corp (BPMX) opened at 0.311 on Wednesday. The company’s 50 day moving average price is $0.39 and its 200 day moving average price is $0.50. Biopharmx Corp has a one year low of $0.19 and a one year high of $1.22. The firm’s market capitalization is $23.05 million.

Separately, ValuEngine raised Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 24th.

WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-biopharmx-corp-bpmx-share-price-updated-updated/1304504.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.